Abstract
The efficacy and toxicity of recombinant human granulocyte colony‐stimulating factor (rh G‐CSF, KRN8601) given subcutaneously was evaluated in patients with advanced lung cancer undergoing intensive chemotherapy. Twenty‐nine and 30 patients with or without prior therapy were enrolled in this study. At dose levels of 50, 90 and 130 μg/m2 of rh G‐CSF for 14 consecutive days after chemotherapy, the mean neutrophil nadir counts, the mean neutrophil nadir ratios and the duration of neutropenia (days of < 1000/mm3) were significantly improved. No significant differences were seen in frequency and duration of febrile episodes (>38°C). When rh G‐CSF is given subcutaneously, the dose required for an equal effect in alleviating neutropenia is 50% of that required when it is given intravenously. The monocyte counts in the peripheral blood were also significantly increased after chemotherapy cycles with rh G‐CSF. The cumulative plasma concentration of rh G‐CSF showed a decrement after 7–9 days despite maintenance of the same dose of rh G‐CSF for the entire 14 days. In conclusion, 50–130 μg/m2 of sc rh G‐CSF increased the neutrophil nadir count and shortened the duration of neutropenia in patients undergoing intensive chemotherapy for lung cancer without intolerable side effects.
Keywords: Recombinant human granulocyte colony‐stimulating factor, Chemotherapy, Lung cancer
Full Text
The Full Text of this article is available as a PDF (366.2 KB).
REFERENCES
- 1. ) Statistics and Information Department, Ministe's Secretariat, Ministry of Health and Welfare . “ Vital Statistics 1989 Japan, Vol. 43 ” ( 1989. ). Kosei‐Tokei‐Kyokai; , Tokyo ( in Japanese ). [Google Scholar]
- 2. ) Morstyn , G. and Burgess , A. W.Hemopoietic growth factors: a review . Cancer Res. , 48 , 5624 – 5637 ( 1988. ). [PubMed] [Google Scholar]
- 3. ) Laver , J. and Moore , M. A. S.Clinical use of recombinant human hematopoietic growth factors . J. Natl Cancer Inst. , 81 , 1370 – 1382 ( 1989. ). [DOI] [PubMed] [Google Scholar]
- 4. ) Groopman , J. E. , Molina , J. M. and Scadden , D. T.Hematopoietic growth factors: biology and clinical applications . N. Engl. J. Med. , 321 , 1449 – 1459 ( 1989. ). [DOI] [PubMed] [Google Scholar]
- 5. ) Gabrilove , J. L. and Jakubowski , A.Granulocyte colony‐stimulating factor: preclinical and clinical studies . Hematol./Oncol. Clin. N. Am. , 3 , 427 – 440 ( 1989. ). [PubMed] [Google Scholar]
- 6. ) Eguchi , K. , Sasaki , S. , Tamura , T. , Sasaki , Y. , Shinkai , T. , Yamada , K. , Soejima , Y. , Fukuda , M. , Fujiwara , Y. , Kunitou , H. , Tobinai , K. , Ohtsu , T. , Suemasu , K. , Takaku , F. and Saijo , N.Dose escalation study of recombinant human granulocyte‐colony‐stimulating factor (KRN 8601) in patients with advanced malignancy . Cancer Res. , 49 , 5221 – 5224 ( 1989. ). [PubMed] [Google Scholar]
- 7. ) Geissler , K. , Harrington , M. , Srivastava , C. , Leemhuis , T. , Tricot , G. and Broxmeyer , H. E.Effects of recombinant human colony stimulating factors (CSF) (granulocyte‐macrophage CSF, granulocyte CSF, and CSF‐1) on human monocyte/macrophage differentiation . J. Immunol. , 143 , 140 – 146 ( 1989. ). [PubMed] [Google Scholar]
- 8. ) Gabrilove , J. L. , Jakubowski , A. , Fain , K. , Grous , J. , Seer , H. , Sternberg , C. , Yagota , A. , Clarkson , B. , Bonilla , M. A. , Ottgen , H. F. , Alton , K. , Boone , T. , Altrock , B. , Welte , K. and Souza , L.Phase I study of granulocyte colony‐stimulating factor in patients with transitional cell carcinoma of the urothelium . J. Clin. Invest. , 82 , 1454 – 1461 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. ) Morstyn , G. , Campbell , L. , Souza , L. M. , Alton , N. K. , Keeth , J. , Green , M. , Sheridan , W. and Metcalf , D.Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy . Lancet , ii , 667 – 672 ( 1988. ). [DOI] [PubMed] [Google Scholar]
- 10. ) Lindeman , A. , Herrmann , F. , Oster , W. , Haffner , G. , Meyenburg , W. , Souza , L. M. and Mertelsmann , R.Hematologic effects of recombinant human granulocyte colony‐stimulating factor in patients with malignancy . Blood , 74 , 2644 – 2651 ( 1989. ). [PubMed] [Google Scholar]
- 11. ) Morstyn , G. , Cambell , L. , Lieschke , G. , Layton , J. E. , Maher , D. , 'Connor , M. , Green , M. , Sheridan , W. , Vincent , M. , Alton , K. , Souza , L. , McGrath , K. and Fox , R. M.Treatment of chemotherapy‐induced neutropenia by subcutaneously administered granulocyte colony‐stimulating factor with optimization of dose and duration of therapy . J. Clin. Oncol. , 7 , 1554 – 1562 ( 1989. ). [DOI] [PubMed] [Google Scholar]
- 12. ) Neidhart , J. , Mangalik , A. , Kohler , W. , Stidley , C. , Saiki , J. , Duncan , P. , Souza , L. and Downing , M.Granulocyte colony‐stimulating factor stimulates recovery of granulocytes in patients receiving dose‐intensive chemotherapy without bone marrow transplantation . J. Clin. Oncol. , 7 , 1685 – 1692 ( 1989. ). [DOI] [PubMed] [Google Scholar]
- 13. ) Layton , J. E. , Hockman , H. , Sheridan , W. P. and Morstyn , G.Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell‐related control of a regulatory growth factor . Blood , 74 , 1303 – 1307 ( 1989. ). [PubMed] [Google Scholar]
- 14. ) Watari , K. , Asano , S. , Shirafuji , N. , Kodo , H. , Ozawa , K. , Takaku , F. and Kamachi , S.Serum granulocyte colony‐stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immuno‐assay . Blood , 73 , 117 – 122 ( 1989. ). [PubMed] [Google Scholar]